GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » CardieX Ltd (ASX:CDX) » Definitions » Price-to-Free-Cash-Flow

CardieX (ASX:CDX) Price-to-Free-Cash-Flow : N/A (As of May. 14, 2024)


View and export this data going back to 2005. Start your Free Trial

What is CardieX Price-to-Free-Cash-Flow?

As of today (2024-05-14), CardieX's share price is A$0.049. CardieX's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.03. Hence, CardieX's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for CardieX's Price-to-Free-Cash-Flow or its related term are showing as below:

During the past 13 years, CardieX's highest Price-to-Free-Cash-Flow Ratio was 18.41. The lowest was 6.14. And the median was 11.83.

ASX:CDX's Price-to-Free-Cash-Flow is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.97
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

CardieX's Free Cash Flow per Share for the six months ended in Dec. 2023 was A$0.01. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was A$-0.03.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -53.40% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -14.00% per year.

During the past 13 years, CardieX's highest 3-Year average Free Cash Flow per Share Growth Rate was 47.70% per year. The lowest was -53.40% per year. And the median was 13.35% per year.


CardieX Price-to-Free-Cash-Flow Historical Data

The historical data trend for CardieX's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CardieX Price-to-Free-Cash-Flow Chart

CardieX Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

CardieX Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of CardieX's Price-to-Free-Cash-Flow

For the Medical Devices subindustry, CardieX's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CardieX's Price-to-Free-Cash-Flow Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, CardieX's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where CardieX's Price-to-Free-Cash-Flow falls into.



CardieX Price-to-Free-Cash-Flow Calculation

CardieX's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=0.049/-0.034
=N/A

CardieX's Share Price of today is A$0.049.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CardieX's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Dec. 2023 was A$-0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

CardieX  (ASX:CDX) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


CardieX Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of CardieX's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


CardieX (ASX:CDX) Business Description

Traded in Other Exchanges
N/A
Address
55 Lime Street, Suite 301, Level 3, Sydney, NSW, AUS, 2000
CardieX Ltd is a global health technology company, developing solutions for health disorders. The AtCor Medical division develops medical devices for measuring arterial stiffness and central blood pressure waveforms based on its patented SphygmoCor technology. It also develops and licenses its Arty platform consisting of physiological and health analytics for wearable devices. It reports in a single segment being sales of cardiovascular devices and services to hospitals, clinics, research institutions, and pharmaceutical companies. The company has three reportable segments by geographic area namely the Americas includes, global pharmaceutical trials business, Europe includes, the Middle East and Africa and the Asia Pacific includes, Asia and Australia/New Zealand.

CardieX (ASX:CDX) Headlines

No Headlines